Clinical Trial Update: A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM [Phase 3]

View source ↗

Summary

Phase 3 trial of ALXN2060 in Japanese participants with symptomatic transthyretin amyloid cardiomyopathy has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• ALXN2060 (acoramidis)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Symptomatic Transthyretin Amyloid Cardiomyopathy | Phase 3 | Status: COMPLETED | Results posted: 2024-12-16